Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity

Cancer Research
V PavetH Gronemeyer

Abstract

Ongoing clinical trials are exploring anticancer approaches based on signaling by TRAIL, a ligand for the cell death receptors DR4 and DR5. In this study, we report on the selective apoptotic effects of multivalent DR5 binding peptides (TRAIL(mim/DR5)) on cancer cells in vitro and in vivo. Surface plasmon resonance revealed up to several thousand-fold increased affinities of TRAIL(mim/DR5)-receptor complexes on generation of divalent and trivalent molecules, the latter of which was achieved with a conformationally restricted adamantane core. Notably, only multivalent molecules triggered a substantial DR5-dependent apoptotic response in vitro. In tumor models derived from human embryonic kidney cells or primary foreskin fibroblasts, TRAIL(mim/DR5) peptides exerted a cancer cell-selective action that could synergize with resveratrol in a manner independent of p53. In a xenograft model of human colon cancer, a divalent TRAIL(mim/DR5) peptide inhibited tumor growth. Our results offer a proof-of-principle for the development of synthetic small molecules to trigger the TRAIL apoptosis pathway for cancer therapy.

References

Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Nov 5, 1997·The Journal of Biological Chemistry·M MacFarlaneE S Alnemri
Feb 14, 2002·Trends in Biochemical Sciences·Jean-Luc BodmerJürg Tschopp
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Erika CretneyMark J Smyth
Jun 5, 2002·Nature Reviews. Cancer·William C Hahn, Robert A Weinberg
Feb 11, 2004·The Journal of Experimental Medicine·Kazuyoshi TakedaMark J Smyth
Nov 13, 2004·Cell Research·Fiona C Kimberley, Gavin R Screaton
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kazuhiro MotokiShiro Kataoka
Oct 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nadeen ZerafaMark J Smyth
Apr 14, 2006·Current Drug Targets·Dominique DelmasNorbert Latruffe
Jul 25, 2006·Journal of Molecular Biology·Bing LiSachdev S Sidhu
Nov 14, 2006·The International Journal of Biochemistry & Cell Biology·Erika CretneyMark J Smyth
May 29, 2007·Oncogene·K TakedaM J Smyth
Oct 3, 2007·Expert Opinion on Therapeutic Targets·Delphine MérinoOlivier Micheau
Oct 24, 2007·The International Journal of Biochemistry & Cell Biology·Emilie Voltz, Hinrich Gronemeyer
Dec 15, 2007·The Journal of Clinical Investigation·Anne Grosse-WildeHenning Walczak
May 13, 2008·Cell Cycle·Niklas Finnberg, Wafik S El-Deiry
Jun 5, 2008·The Journal of Clinical Investigation·Avi Ashkenazi, Roy S Herbst
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Avi AshkenaziS Gail Eckhardt
Dec 25, 2008·Cancer Biology & Therapy·Kageaki KuribayashiWafik S El-Deiry
Feb 6, 2009·Apoptosis : an International Journal on Programmed Cell Death·Thomas Newsom-DavisHenning Walczak
Apr 30, 2009·Advances in Experimental Medicine and Biology·Yvonne M AngellChristopher P Holmes

❮ Previous
Next ❯

Citations

Nov 13, 2010·Cell Death and Differentiation·A MorizotO Micheau
Oct 12, 2010·Oncogene·V PavetH Gronemeyer
Sep 21, 2010·Chemical Communications : Chem Comm·Katarzyna GorskaNicolas Winssinger
Apr 13, 2012·The Journal of Biological Chemistry·Christopher C ValleyJonathan N Sachs
Jan 12, 2011·Cancer Letters·Pamela M Holland
Mar 18, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Fengtao LiuYuanfang Ma
May 4, 2013·British Journal of Pharmacology·O MicheauF Dufour
Jun 4, 2014·Biomaterials·Giuseppe LamannaAlberto Bianco
Jan 11, 2012·Biochemical Pharmacology·Luis Martinez-LostaoJavier Naval
Jan 15, 2015·Nano Letters·Al Batoul ZakariaGuillaume Herlem
Oct 27, 2016·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yves Claude GuillaumeClaire André
Apr 28, 2011·Experimental Biology and Medicine·Konstantinos ArgirisMahvash Tavassoli
Apr 27, 2017·Nanoscale·H BelkahlaO Micheau
Jan 26, 2017·Journal of Molecular Recognition : JMR·Yves Claude Guillaume, Claire André
Dec 3, 2014·Journal of Peptide Science : an Official Publication of the European Peptide Society·Maxime Grillaud, Alberto Bianco
Sep 12, 2014·Chembiochem : a European Journal of Chemical Biology·Dorith ClaesWolfgang Maison
Dec 15, 2012·Chemistry : a European Journal·Giuseppe LamannaAlberto Bianco
May 1, 2010·Chembiochem : a European Journal of Chemical Biology·Christian-H Küchenthal, Wolfgang Maison
Oct 20, 2017·Cell Death & Disease·Yelyzaveta ShlyakhtinaHinrich Gronemeyer
Mar 19, 2016·Angewandte Chemie·Bernhard ValldorfHarald Kolmar
Jun 18, 2019·Chembiochem : a European Journal of Chemical Biology·Hendrik SchneiderHarald Kolmar
Feb 12, 2017·Cell Death and Differentiation·Florent DufourOlivier Micheau
Aug 24, 2018·Acta Biochimica Et Biophysica Sinica·Jinqing HuXiumei Zhou
May 29, 2018·Archives of Pharmacal Research·Kyoung Ah MinMeong Cheol Shin
Oct 25, 2017·Antibodies·Agathe Dubuisson, Olivier Micheau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.